Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01031641 · ClinicalTrials.gov registry record

Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing

A clinical trial of Lymphomas and Leukemias, sponsored by National Cancer Institute (NCI).

Completed
Registry status
1,448
Enrollment target
2
Study locations

NCT01031641: Completed study of Lymphomas and Leukemias, sponsored by National Cancer Institute (NCI).

NCT01031641 is a study of Lymphomas and Leukemias that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,448 participants, above the 888-participant average among 7 other Lymphomas trials with a reported enrollment target (63% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01031641, a study of Lymphomas and Leukemias, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
1,448 participants
Enrollment target
2
Study locations

Study Summary

Background: * Currently, National Cancer Institute treatment trials use clinical staff reporting to monitor adverse side effects. The clinical staff reports draw on items from the Common Terminology Criteria for Adverse Events (CTCAE). * Several of the items in the CTCAE can be adapted for use in patient self-reporting of side effects. Researchers are interested in developing a patient-reported outcome (PRO) approach to the CTCAE. Objectives: * To develop questions that can be used to create a patient-reported outcome version of the CTCAE (PRO-CTCAE). * To evaluate patient comprehension of and test the usefulness of the PRO-CTCAE questions among diverse groups of patients. Eligibility: * Individuals 18 years of age and older who are receiving chemotherapy or radiotherapy as cancer treatment. * Participants must be able to speak and understand English. Design: * Researchers will conduct up to three rounds of interviews with patients currently receiving chemotherapy or radiation therapy treatments for cancer. * Participants will be recruited independently from four different clinical treatment sites. At least 25 percent of patients will have an educational attainment of high school or less. * Each patient will complete a two-part protocol, including a set of PROs that will be followed by a series of questions to evaluate patient comprehension, memory, perceived clarity, and judgment of the PROs. * The research will be completed in approximately 1 hour, and participants will receive a small amount of compensation for their time and participation.

Primary Outcome

Patient report of symptom experience

Study Locations (2)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 1,448 participants
Start Date 2009-11-19
Est. Completion 2020-07-16
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT01031641 record still lists

NCT01031641 is an observational study that tracks outcomes without assigning an intervention. Its 1,448 participants enrollment target places it among the larger protocols in the corpus, above the 888-participant average among 7 other Lymphomas trials with a reported enrollment target (63% higher).

The record links to 3 conditions, with Lymphomas appearing as the primary indexed condition, and to 0 interventions.

NCT01031641 reports a single indexed study location in New York, Texas.

Frequently Asked Questions

What is clinical trial NCT01031641 about?

NCT01031641 is a clinical study titled "Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing". Background: * Currently, National Cancer Institute treatment trials use clinical staff reporting to monitor adverse side effects. The clinical staff reports draw on items from the Common Terminology Criteria for Adverse Events (CTCAE). * Several of the items in the CTCAE can be adapted for use in p...

What is the current status of trial NCT01031641?

This trial is currently completed. The enrollment target is 1,448 participants. The study started on 2009-11-19. Estimated completion is 2020-07-16.

What conditions does trial NCT01031641 study?

This clinical trial studies the following conditions: Lymphomas, Leukemias, Multiple Cancers.

Who is sponsoring clinical trial NCT01031641?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01031641 being conducted?

This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphomas

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04566328 · 1,450 participants · Phase 3

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • NCT05229341 · 1,450 participants · NA

    Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

  • NCT05910268 · 1,450 participants · NA

    Peru Decentralized HIV Care

  • NCT06305312 · 1,450 participants · NA

    Community Services Navigation to Advance Health Equity in Breast Cancer Screening

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01031641, the US trial registry maintained by the National Library of Medicine. NCT01031641 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.